ADC Therapeutics SA - 8-K Filing
ADC Therapeutics held its annual general meeting on June 1, 2026, where shareholders approved all proposals including financial statements, executive compensation, re-election of directors and auditors, and amendments to the company's articles of association. The board was authorized a maximum aggregate compensation of $2.5 million for their term through 2027, while executives received fixed and variable compensation caps set at $2.6 million and $5.5 million respectively. (Items: 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $ADCT